China Nucleic Acid Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Products (Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers, RNA interference [RNAi] and short interfering RNAs [siRNAs], and Others), By Application (Monogenetic disorders, and Multi-genetic disorders), By End User (Hospitals and Clinics and Academic and Research Institutes), and China Nucleic Acid Therapeutics Market Insights, Industry Trend, Forecasts to 2033.

China Nucleic Acid Therapeutics Market Insights Forecasts to 2033

• The China Nucleic Acid Therapeutics Market is Growing at a CAGR of 11.56% from 2023 to 2033
• The China Nucleic Acid Therapeutics Market Size is Expected to Reach a Significant Share by 2033

The China Nucleic Acid Therapeutics Market is anticipated to reach a significant share by 2033, growing at a CAGR of 11.56% from 2023 to 2033.

Market Overview

China nucleic acid therapeutics market refers to the sector involved in the development, production, and commercialization of therapies based on nucleic acids, such as DNA, RNA, and related molecules, to treat various diseases. These include genetic disorders, cancers, and viral infections, with key technologies like RNA interference (RNAi), gene therapy, and RNA-based treatments playing a major role in therapeutic advancements. With rapid technological advancements, such as improvements in gene editing tools like CRISPR, and enhanced delivery systems for RNA therapeutics, the market is poised for innovation and growth. Opportunities abound in the development of personalized medicine, where therapies can be tailored to individual genetic profiles, providing more effective treatments. Additionally, increasing government support, favorable regulatory frameworks, and growing investments in research and clinical trials are expected to contribute to the market's future growth.

Report Coverage

This research report categorizes the market for the China nucleic acid therapeutics market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the China nucleic acid therapeutics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the China nucleic acid therapeutics market.

Driving Factors

The growing adoption of personalized medicine, where treatments are tailored to individual genetic profiles, is also a key driver, offering more effective and customized care. Furthermore, strong government support and favorable regulatory frameworks are accelerating research and development activities in the sector, making it easier for companies to bring new therapies to market. Additionally, increased investments from both private and public sectors, alongside collaborations between biotech companies and academic institutions, are driving innovation and expanding the therapeutic potential of nucleic acid-based treatments.

Restraining Factors

The complexity of these therapies, including the need for specialized delivery systems and personalized approaches, also poses significant technical and logistical hurdles.

Market Segmentation

The China nucleic acid therapeutics market share is classified into products, application, and end user.

• The RNA interference [RNAi] and short interfering RNAs [siRNAs] segment accounted for the highest revenue share in 2023 and is expected to grow at a remarkable CAGR during the forecast period.

The China nucleic acid therapeutics market is segmented by products into anti-sense oligonucleotides (ASOs) and DNA aptamers, RNA interference [RNAi] and short interfering RNAs [siRNAs], and others. Among these, the RNA interference [RNAi] and short interfering RNAs [siRNAs] segment accounted for the highest revenue share in 2023 and is expected to grow at a remarkable CAGR during the forecast period. This growth is driven by the significant therapeutic potential of RNAi and siRNAs in targeting specific genes associated with various diseases, including cancers, genetic disorders, and viral infections. Technological advancements, such as improvements in RNA delivery systems and the ongoing development of RNA-based therapeutics, are further propelling this segment’s expansion.

• The monogenetic disorders segment accounted for the largest market share in 2023 and is expected to grow at a substantial CAGR during the forecast period.

The China nucleic acid therapeutics market is segmented by application into monogenetic disorders, and multi-genetic disorders. Among these, the monogenetic disorders segment accounted for the largest market share in 2023 and is expected to grow at a substantial CAGR during the forecast period. The growth can be attributed to the increasing prevalence of monogenetic disorders, such as cystic fibrosis, Duchenne muscular dystrophy, and sickle cell anemia, which are caused by mutations in a single gene. The ability of nucleic acid therapeutics, such as gene therapies and RNA-based treatments, to target and correct these specific genetic mutations has led to significant advancements in the treatment of these disorders.

• The hospitals and clinics segment accounted for the leading revenue share in 2023 and is expected to grow at a significant CAGR during the forecast period.

The China nucleic acid therapeutics market is segmented by end user into hospitals and clinics and academic and research institutes. Among these, the hospitals and clinics segment accounted for the leading revenue share in 2023 and is expected to grow at a significant CAGR during the forecast period. The growth is largely driven by the increasing adoption of nucleic acid-based therapies in clinical settings for the treatment of various genetic disorders, cancers, and viral infections. Hospitals and clinics play a crucial role in administering these advanced therapies, as they are equipped with the necessary infrastructure, medical professionals, and technology to support the delivery of complex nucleic acid treatments.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the China nucleic acid therapeutics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Thermo Fisher Scientific Inc.
• Qaigen NV
• Genzyme Sanofi
• Protagonist Therapeutics
• Merck KGaA
• Benitec Biopharma
• Agilent Technologies
• Sarpeta Therapeutics
• NOVARTIS AG.
• Silence Therapeutics
• Arbutus Biopharma
• Copernicus
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In August 2023, Novartis introduced its inclisiran sodium injection to the Chinese market following approval from the National Medical Products Administration (NMPA). Inclisiran sodium is a siRNA lipid-lowering drug.

Market Segment

This study forecasts revenue at China, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the China nucleic acid therapeutics market based on the below-mentioned segments:

China Nucleic Acid Therapeutics Market, By Products

• Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers
• RNA interference [RNAi] and short interfering RNAs [siRNAs]
• Others

China Nucleic Acid Therapeutics Market, By Application

• Monogenetic disorders
• Multi-genetic disorders

China Nucleic Acid Therapeutics Market, By End User

• Hospitals and Clinics
• Academic and Research Institutes